US Equities Tracker: Restructuring and Pipeline Milestones Shape H2 2026Global Report·2 days ago, 04:18 AMSFM+8.00%CGTX-3.57%
The Unbundling of the Long Tail: Structural Realities at the Edges of the Value ChainGlobal Report·Jul 21 at 04:13 AMNUE+0.70%BTG+1.04%
Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR websitePUBT·Jul 13 at 06:31 AMCGTX-3.57%
Hippo deploys Cognition’s Devin AI software engineer across insurance operationsPUBT·Jun 25 at 08:02 AMHIPO+7.00%CGTX-3.57%
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·Jun 24 at 12:05 PMATLN0.00%PLSM-1.09%
Cognition Therapeutics targets mid-2027 start for Phase 3 zervimesine trial in DLB psychosisPUBT·Jun 24 at 06:30 AMCGTX-3.57%
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes | CGTX Stock NewsStockTitan·Jun 23 at 10:30 PMCGTX-3.57%
Cognition Therapeutics shareholders elect Aaron Fletcher, Lisa Ricciardi as Class II directorsPUBT·Jun 18 at 07:06 AMCGTX-3.57%
World Wide Technology Launches ‘Defending at the Speed of AI’ Initiative with Horizon3.ai, Empirical Security, Infoblox, and CognitionUnusual Whales·Jun 16 at 09:07 AMCGTX-3.57%
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045Unusual Whales·Jun 16 at 06:32 AMCGTX-3.57%
Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027TradingView·Jun 4 at 07:03 AMCGTX-3.57%
